| scholarly article | Q13442814 |
| P2093 | author name string | M Li | |
| C Lane | |||
| R L Garcea | |||
| R C Rose | |||
| J A Suzich | |||
| W I White | |||
| P2860 | cites work | Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line | Q29547520 |
| Structures of bovine and human papillomaviruses. Analysis by cryoelectron microscopy and three-dimensional image reconstruction | Q30447715 | ||
| Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas | Q33707499 | ||
| Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group | Q34313864 | ||
| Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. | Q35840539 | ||
| Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition | Q35860748 | ||
| Expression of the human papillomavirus type 11 L1 capsid protein in Escherichia coli: characterization of protein domains involved in DNA binding and capsid assembly | Q35880936 | ||
| Three-dimensional structure of vaccinia virus-produced human papillomavirus type 1 capsids | Q36622630 | ||
| Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins | Q36639439 | ||
| Cottontail rabbit papillomavirus L1 protein-based vaccines: protection is achieved only with a full-length, nondenatured product | Q36650162 | ||
| Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles | Q36685977 | ||
| Monoclonal antibody-mediated neutralization of infectious human papillomavirus type 11 | Q36793675 | ||
| Antibody-mediated neutralization in vivo of infectious papillomaviruses | Q36809093 | ||
| Laboratory production in vivo of infectious human papillomavirus type 11 | Q36884907 | ||
| Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic | Q37353496 | ||
| A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. | Q37604389 | ||
| Quantitative disassembly and reassembly of human papillomavirus type 11 viruslike particles in vitro. | Q39577044 | ||
| Two amino acid residues confer type specificity to a neutralizing, conformationally dependent epitope on human papillomavirus type 11. | Q39875296 | ||
| Prospects for a vaccine against human papillomavirus | Q40416983 | ||
| Human pathogenic papillomavirus types: an update | Q40763787 | ||
| Molecular pathogenesis of cancer of the cervix and its causation by specific human papillomavirus types | Q40763810 | ||
| Serological differentiation of human papillomavirus types 11, 16 and 18 using recombinant virus-like particles | Q41019646 | ||
| Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies | Q41172103 | ||
| Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization | Q41203441 | ||
| Titration of HPV-11 Infectivity and Antibody Neutralization Can Be Measured In Vitro | Q41301563 | ||
| Human papillomavirus immunology and vaccine prospects | Q41344675 | ||
| The causal link between HPV and cervical cancer and its implications for prevention of cervical cancer. | Q41354966 | ||
| HPV-1 Capsids Expressed in Vitro Detect Human Serum Antibodies Associated with Foot Warts | Q41540444 | ||
| Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types | Q44918470 | ||
| Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera | Q45780898 | ||
| Assembled baculovirus-expressed human papillomavirus type 11 L1 capsid protein virus-like particles are recognized by neutralizing monoclonal antibodies and induce high titres of neutralizing antibodies | Q45789709 | ||
| Structure of simian virus 40 at 3.8-A resolution | Q45861692 | ||
| Antibody-Mediated Neutralization of Human Papillomavirus Type 11 (HPV-11) Infection in the Nude Mouse: Detection of HPV-11 mRNAs | Q67485675 | ||
| National Institutes of Health Consensus Development Conference Statement: cervical cancer, April 1-3, 1996. National Institutes of Health Consensus Development Panel | Q73046965 | ||
| P433 | issue | 7 | |
| P921 | main subject | antibody | Q79460 |
| P304 | page(s) | 6151-6154 | |
| P577 | publication date | 1998-07-01 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies | |
| P478 | volume | 72 |
| Q36673310 | A direct comparison of human papillomavirus type 16 L1 particles reveals a lower immunogenicity of capsomeres than viruslike particles with respect to the induced antibody response |
| Q37604412 | A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11. |
| Q59329445 | Advances in Designing and Developing Vaccines, Drugs and Therapeutic Approaches to Counter Human Papilloma Virus |
| Q43096878 | Analysis of modified human papillomavirus type 16 L1 capsomeres: the ability to assemble into larger particles correlates with higher immunogenicity |
| Q37242405 | Antigenic presentation of heterologous epitopes engineered into the outer surface-exposed helix 4 loop region of human papillomavirus L1 capsomeres |
| Q28743261 | Capsomer vaccines protect mice from vaginal challenge with human papillomavirus |
| Q37307576 | Cervarix: a vaccine for the prevention of HPV 16, 18-associated cervical cancer. |
| Q60441064 | Cervical cancer screening |
| Q33813986 | Characterization of a major neutralizing epitope on human papillomavirus type 16 L1 |
| Q35079915 | Characterization of neutralizing epitopes within the major capsid protein of human papillomavirus type 33. |
| Q35155333 | Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16 |
| Q37226543 | Chimeric papillomavirus-like particles expressing a foreign epitope on capsid surface loops |
| Q41676237 | Crystal Structures of Two Immune Complexes Identify Determinants for Viral Infectivity and Type-Specific Neutralization of Human Papillomavirus |
| Q34477334 | Development of a highly thermostable, adjuvanted human papillomavirus vaccine |
| Q41269236 | Development of chimeric candidate vaccine against HPV18: a proof of concept. |
| Q56967486 | Emerging human papillomavirus vaccines |
| Q42785059 | Evolutionary and structural analyses of alpha-papillomavirus capsid proteins yields novel insights into L2 structure and interaction with L1. |
| Q37280045 | Expression and characterization of HPV-16 L1 capsid protein in Pichia pastoris |
| Q33298684 | Expression of HPV-11 L1 protein in transgenic Arabidopsis thaliana and Nicotiana tabacum |
| Q33723292 | Expression of HPV-16 L1 capsomeres with glutathione-S-transferase as a fusion protein in tobacco plastids: an approach for a capsomere-based HPV vaccine |
| Q35235035 | How will HPV vaccines affect cervical cancer? |
| Q37271947 | Human papillomavirus infection and the primary and secondary prevention of cervical cancer. |
| Q39742082 | Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice |
| Q40239266 | Human papillomavirus vaccine update |
| Q33840918 | Human papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA. |
| Q33908917 | Humoral immune response recognizes a complex set of epitopes on human papillomavirus type 6 l1 capsomers |
| Q33853398 | Immunization with a pentameric L1 fusion protein protects against papillomavirus infection |
| Q36022468 | Immunizing against Anogenital Cancer: HPV Vaccines |
| Q73235255 | Infection with Human Papillomavirus: Update on Epidemiology, Diagnosis, and Treatment |
| Q42193505 | Influence of Brucella abortus lipopolysaccharide as an adjuvant on the immunogenicity of HPV-16 L1VLP vaccine in mice. |
| Q37391175 | Listeria monocytogenes delivery of HPV-16 major capsid protein L1 induces systemic and mucosal cell-mediated CD4+ and CD8+ T-cell responses after oral immunization |
| Q33834872 | Maturation of papillomavirus capsids |
| Q37274559 | New approaches to prophylactic human papillomavirus vaccines for cervical cancer prevention |
| Q35165017 | Non-carrier nanoparticles adjuvant modular protein vaccine in a particle-dependent manner. |
| Q54263650 | Opportunities and challenges for human papillomavirus vaccination in cancer. |
| Q35182055 | Oral immunogenicity of human papillomavirus-like particles expressed in potato |
| Q33614425 | Papillomavirus prophylactic vaccines: established successes, new approaches |
| Q34011494 | Perspectives for preventive and therapeutic HPV vaccines |
| Q34975090 | Plant-produced cottontail rabbit papillomavirus L1 protein protects against tumor challenge: a proof-of-concept study. |
| Q33575647 | Potential anti-HPV and related cancer agents from marine resources: an overview |
| Q36314993 | Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2. |
| Q90079811 | Public-private knowledge transfer and access to medicines: a systematic review and qualitative study of perceptions and roles of scientists involved in HPV vaccine research |
| Q36313476 | Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever |
| Q96304267 | Single-administration, thermostable human papillomavirus vaccines prepared with atomic layer deposition technology |
| Q33812653 | Subviral particle as vaccine and vaccine platform |
| Q54080674 | Transplastomic expression of a modified human papillomavirus L1 protein leading to the assembly of capsomeres in tobacco: a step towards cost-effective second-generation vaccines. |
| Q34054427 | Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection |
| Q47604101 | Vaccines for cervical cancer |
| Q37328475 | Virus-like particles for the prevention of human papillomavirus-associated malignancies |
Search more.